Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.
Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.
复制标题
循环肿瘤 DNA 对预测接受一线治疗的弥漫性大 B 细胞淋巴瘤患者结果的临床意义
DOI：
10.1186/s12916-022-02562-3
复制
发表时间：
2022-10-25
期刊：
影响因子：
9.3
通讯作者：
Zhu, Jun
中科院分区：
文献类型：
--
作者：
Li, Miaomiao;Mi, Lan;Wang, Chunyang;Wang, Xiaojuan;Zhu, Jianhua;Qi, Fei;Yu, Hui;Ye, Yingying;Wang, Dedao;Cao, Jiaowu;Hu, Dingyao;Yang, Quanyu;Zhao, Dandan;Ma, Tonghui;Song, Yuqin;Zhu, Jun
BackgroundCirculating tumor DNA (ctDNA) has been proven to be a promising tumor-specific biomarker in solid tumors, but its clinical utility in risk stratification and early prediction of relapse for diffuse large B cell lymphoma (DLBCL) has not been well explored.MethodsHere, using a lymphoma-specific sequencing panel, we assessed the prognostic and predictive utilities of ctDNA measurements before, during, and after first-line therapy in 73 Chinese DLBCL patients.ResultsThe pretreatment ctDNA level serving as an independent prognostic factor for both progression-free survival (PFS, adjusted HR 2.47;p= 0.004) and overall survival (OS, adjusted HR 2.49;p= 0.011) was confirmed in our cohort. Furthermore, the patients classified as molecular responders who presented a larger decrease in ctDNA levels after the initial two treatment cycles had more favorable PFS (unreached vs. 6.25 months; HR 5.348;p= 0.0015) and OS (unreached vs. 25.87; HR 4.0;p= 0.028) than non-responders. In addition, interim ctDNA clearance may be an alternative noninvasive method of positron emission tomography and computed tomography (PET-CT) for predicting better PFS (HR 3.65;p= 0.0033) and OS (HR 3.536;p= 0.016). We also demonstrated that posttreatment ctDNA was a sensitive indicator for detecting minimal residual disease (MRD) in patients with a high risk of recurrence (HR 6.471;p= 0.014), who were otherwise claimed to achieve radiographic CR (complete remission).ConclusionsCtDNA is a promising noninvasive tool for prognosis prediction, response assessment, and early relapse prediction of first-line treatment in DLBCL patients.
登录
查看更多内容
影响因子：
51.1
作者：
Roschewski, Mark;Dunleavy, Kieron;Pittaluga, Stefania;Moorhead, Martin;Pepin, Francois;Kong, Katherine;Shovlin, Margaret;Jaffe, Elaine S.;Staudt, Louis M.;Lai, Catherine;Steinberg, Seth M.;Chen, Clara C.;Zheng, Jianbiao;Willis, Thomas D.;Faham, Malek;Wilson, Wyndham H.
通讯作者：
Wilson, Wyndham H.
影响因子：
5.2
作者：
Larribère L;Martens UM
通讯作者：
Martens UM
影响因子：
45.3
作者：
Moskowitz, Craig H.;Schoeder, Heiko;Zelenetz, Andrew D.
通讯作者：
Zelenetz, Andrew D.
DOI：
10.1073/pnas.1921187117
发表时间：
2020-03-17
影响因子：
11.1
作者：
Choi, Jaewoo;Phelan, James D.;Staudt, Louis M.
通讯作者：
Staudt, Louis M.
通过免疫化学疗法治疗的弥漫性大B细胞淋巴瘤患者的改良预后模型。
影响因子：
2.9
作者：
Zhao P;Zhu L;Li L;Zhou S;Qiu L;Qian Z;Xu W;Zhang H
通讯作者：
Zhang H